Skip to main content

Volinanserin









Volinanserin


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search




























































Volinanserin
MDL-100,907 structure.png
Clinical data
Synonyms MDL-100,907
ATC code
  • None
Identifiers
CAS Number
  • 139290-65-6

PubChem CID
  • 5311271
IUPHAR/BPS
  • 185
ChemSpider
  • 4470782
UNII
  • EW71EE171J
ChEMBL
  • ChEMBL74355
ECHA InfoCard
100.123.797 Edit this at Wikidata
Chemical and physical data
Formula
C22H28FNO3
Molar mass 373.46 g/mol
3D model (JSmol)
  • Interactive image

Volinanserin (INN) (developmental code name MDL-100,907) is a highly selective 5-HT2A receptor antagonist that is frequently used in scientific research to investigate the function of the 5-HT2A receptor.[1][2][3] It was also tested in clinical trials as a potential antipsychotic,[4][5]antidepressant,[6] and treatment for insomnia but was never marketed.[7]



See also[edit]



  • Eplivanserin

  • Glemanserin

  • Ketanserin

  • Pimavanserin

  • Ritanserin



References[edit]





  1. ^ Schmidt CJ, Fadayel GM, Sullivan CK, Taylor VL (November 1992). "5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine". European Journal of Pharmacology. 223 (1): 65–74. doi:10.1016/0014-2999(92)90819-P. PMID 1362159..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ Herth MM, Kramer V, Piel M, Palner M, Riss PJ, Knudsen GM, Rösch F (April 2009). "Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET". Bioorganic & Medicinal Chemistry. 17 (8): 2989–3002. doi:10.1016/j.bmc.2009.03.021. PMID 19329329.


  3. ^ Nic Dhonnchadha BA, Fox RG, Stutz SJ, Rice KC, Cunningham KA (April 2009). "Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model". Behavioral Neuroscience. 123 (2): 382–96. doi:10.1037/a0014592. PMC 3830454. PMID 19331461.


  4. ^ Offord SJ, Wong DF, Nyberg S (August 1999). "The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action". Journal of Clinical Pharmacology. Suppl: 17S–24S. doi:10.1002/j.1552-4604.1999.tb05933.x. PMID 10434243.


  5. ^ Dennis S. Charney; Eric J. Nestler; Pamela Sklar; Joseph D. Buxbaum (July 2013). Neurobiology of Mental Illness. OUP USA. p. 767. ISBN 9780199934959.


  6. ^ Marek GJ, Martin-Ruiz R, Abo A, Artigas F (December 2005). "The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine". Neuropsychopharmacology. 30 (12): 2205–15. doi:10.1038/sj.npp.1300762. PMID 15886717.


  7. ^ Teegarden BR, Al Shamma H, Xiong Y (2008). "5-HT(2A) inverse-agonists for the treatment of insomnia". Current Topics in Medicinal Chemistry. 8 (11): 969–76. doi:10.2174/156802608784936700. PMID 18673166.

















Retrieved from "https://en.wikipedia.org/w/index.php?title=Volinanserin&oldid=840748986"





Navigation menu

























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.952","walltime":"1.150","ppvisitednodes":{"value":5249,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":410245,"limit":2097152},"templateargumentsize":{"value":3321,"limit":2097152},"expansiondepth":{"value":14,"limit":40},"expensivefunctioncount":{"value":3,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":21970,"limit":5000000},"entityaccesscount":{"value":3,"limit":400},"timingprofile":["100.00% 721.130 1 -total"," 52.89% 381.405 1 Template:Drugbox"," 35.85% 258.525 1 Template:Infobox"," 23.34% 168.299 25 Template:Navbox"," 22.99% 165.806 1 Template:Reflist"," 18.87% 136.105 6 Template:Cite_journal"," 10.03% 72.295 16 Template:Unbulleted_list"," 8.30% 59.868 1 Template:Antidepressants"," 7.72% 55.703 1 Template:Navbox_with_collapsible_groups"," 7.07% 50.989 1 Template:Serotonergics"]},"scribunto":{"limitreport-timeusage":{"value":"0.304","limit":"10.000"},"limitreport-memusage":{"value":5472043,"limit":52428800}},"cachereport":{"origin":"mw1271","timestamp":"20181215181803","ttl":1900800,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":79,"wgHostname":"mw1241"});});

Popular posts from this blog

Full-time equivalent

Bicuculline

さくらももこ